Zimmer Biomet’s semi-autonomous Monogram system has FDA clearance, and Wells Fargo cited its potential revenue contribution when it moved the stock to Overweight from Equal Weight Tuesday.
Monogram Technologies became part of Zimmer Biomet in a 2025 transaction valued at $177 million.
The semi-autonomous system received clearance from the Food and Drug Administration (FDA).



